Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon added to standard treatment for hospitalized high-risk adults with COVID-19 in Qom
IRCT20160118026097N3Phase 3Completed
- Sponsor
- Qom University of Medical Sciences
- Start
- Mar 2020
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of interferon beta-1b in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Qom University of Medical Sciences. Primary endpoint: Death within 30 days of hospitalization. Started Mar 2020; status: completed.
02
Drugs
interferon beta-1b
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20160118026097N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20160118026097N3.